Related Experiment Video
Updated: Aug 10, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Rationale for antiplatelet therapy in patients with atherothrombotic disease
1St George's Hospital Medical School, St George's Hospital, London, UK.
Insights
Atherothrombosis, a leading cause of death, involves blood clots in arteries. Antiplatelet agents like clopidogrel show promise in preventing these clots with minimal side effects.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Thrombosis Research
Background:
- Atherosclerosis and superimposed thrombosis (atherothrombosis) are primary causes of morbidity and mortality in developed nations.
- Evidence suggests atherothrombosis is a unified process across different vascular beds (cardiac, cerebral, peripheral).
- Effective therapies for atherothrombosis include antihypertensives, lipid-lowering agents, and antiplatelet agents.
Purpose of the Study:
- To review the efficacy and safety of various antiplatelet agents used in treating atherothrombosis.
- To highlight the role of different classes of antiplatelet drugs, including ADP receptor antagonists, GpIIb/IIIa antagonists, cyclo-oxygenase inhibitors, and prostacyclin analogues.
Main Methods:
- Review of clinical evidence and ongoing testing of antiplatelet agents.
- Analysis of efficacy and safety profiles of different antiplatelet drug categories.
- Comparison of therapeutic outcomes for various antiplatelet interventions.
Main Results:
- Clopidogrel, an ADP receptor antagonist, currently demonstrates favorable antithrombotic results with a good safety profile.
- Ongoing clinical trials are defining the efficacy and safety of multiple antiplatelet agents.
- Various subcategories of antiplatelet agents are under investigation for atherothrombosis treatment.
Conclusions:
- Antiplatelet therapy is a critical component in managing atherothrombosis.
- Clopidogrel represents a leading option among current antiplatelet agents.
- Combination therapies involving different antiplatelet agents may offer enhanced safety and efficacy in the future.
Abstract:
The most common cause of morbidity and mortality in developed countries results from atherosclerosis and superimposed thrombosis (atherothrombosis) leading to partial or complete vascular occlusion. Much evidence supports the idea that all atherothrombosis is similar, regardless of which vascular bed it occurs in. Thus, similar therapies may be used for patients with symptomatic cardiac, cerebral, or peripheral vascular disease. The types of agents that have shown efficacy in atherothrombosis include antihypertensives, lipid-lowering agents and antiplatelet agents. The focus of this article is on the antiplatelet agents, of which there are several subcategories, including ADP receptor antagonists, GpIIb/IIIa antagonists, cyclo-oxygenase inhibitors and prostacyclin analogues. Clinical testing of these agents is ongoing and the efficacy and safety of the various agents are being defined. To date, the ADP receptor antagonist, clopidogrel, appears to provide the best antithrombotic result with the fewest side effects. Further testing may reveal that combinations of the various forms of antiplatelet agents may provide even further improvements on safety and efficacy.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care